Hrt Financial LP Bluebird Bio, Inc. Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.91 - $1.75 $57,856 - $111,263	63,579 New	63,579 $81,000
Q3 2023 Nov 13, 2023	BUY	$3.02 - $4.05 $51,352 - $68,866	17,004 Added 15.04%	130,097 $395,000
Q2 2023 Aug 11, 2023	BUY	$2.79 - $5.03 $315,529 - $568,857	113,093 New	113,093 $372,000
Q4 2022 Feb 10, 2023	BUY	$5.77 - $8.49 $2.09 Million - $3.08 Million	362,544 New	362,544 $2.51 Million
Q2 2022 Aug 12, 2022	BUY	$2.94 - $5.23 $2.35 Million - $4.17 Million	798,048 New	798,048 $3.3 Million
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $337,113 - $412,795	-18,687 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $310,017 - $633,302	18,687 New	18,687 $563,000
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $223,904 - $350,521	-3,765 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $127,790 - $177,278	1,685 Added 81.01%	3,765 $478,000
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $134,035 - $216,548	2,080 New	2,080 $327,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.